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Stevens Johnson Syndrome in Pakistan: a Ten-Year Survey
Y. I. Ahmed, S. Azeem, O. Khan, T. H. Majid, D. Ahmed, A. Amin, A. Mahmood, K. Hameed
Department of Medicine, The Aga Khan University Hospital, Karachi.

Abstract
Objective: A pre-tested questionnaire-based, retrospective study to highlight the causative factors, mode of
presentation, complications and outcome of patients with Stevens Johnson syndrome.
Setting: Aga Khan University Hospital over a 10 year period.
Methods: All case records with a diagnosis of Steven Johnson Syndrome in the period 1990 to 2000 were
retrospectively reviewed. Data was retrieved on a comprehensive questionnaire. The demographic variatbles
and drugs taken within the previous 21 days were noted. Date analysis was done by Epi-Info Version 6.0.
Results: Of the 101studied patient files, the most common offender was found to be the Penicillins as a group
and Sulfadoxine-Pyrimethamine (Fansidar) when considering all drugs individually. Most common complications
included electrolyte disturbances (13.9%) and congestive heart failure (6.9%). Mortality rate was high at 10.1%.
Conclusion: SJS was found to be a rare condition but having a mortality rate of 10.1%. As it can be induced by
a large number of drugs, caution should be practiced while prescribing (JPMA 54:312;2004).

Introduction
Stevens Johnson Syndrome (SJS) is a generalized, multisystemic hypersensitivity reaction usually to drug exposure in
which skin and mucous membrane lesions are early
manifestations. It was first fully described by Stevens and
Johnson in 19221 and is a potentially life threatening illness
considered to be part of the erythema multiform spectrum.
Usually it is a self-limiting disease. No studies, pertaining to a
large number of patients over a significant time period have been
done in Pakistan that have investigated the eitiologies and course
of Stevens Johnson Syndrome. Western reports represent their
local experiences and drug prescribing. In addition to this, and
probably most importantly, the mortality rate is not known in this
part of the world.

Patients and Methods
Case Selection
A retrospective review of all the cases seen at the Aga
Khan University Hospital, with a diagnosis of Stevens Johnson
Syndrome (SJS) during 1990-2000 was carried out. Data was
obtained from the patients' files. A total of 187 patients were
identified with a discharge diagnosis of Stevens Johnson
syndrome according to the International Classification of
Diseases code ICD-9-CM 695.1. Since the ICD-9-CM code for
erythema multiforme includes other illnesses in addition to
Stevens Johnson syndrome and because these illnesses are
occasionally misdiagnosed, the patients' primary medical records
were sought to confirm whether a skin disease compatible with
Stevens Johnson syndrome was present or not. Stevens Johnson
syndrome was identified according to the following strict criteria
of: (1) involvement of at least 2 different mucous membrane
sites; (2) erosions covering >10% but <20% of the body surface

area and (3) visible iris and target lesions. These criteria were
assessed by reviewing patient charts, where these lesions had
been professionally and precisely documented by a
dermatologist.
Data Collection
To gather clinical information, comprehensive data
collection was carried out, using a questionnaire that was
designed after an extensive literature review using the University
Library, Medline and the Internet. The questionnaire, amongst
other things, included demographic variables, history of drug
intake, signs and symptoms and ultimate outcome. A drug
causally related to the condition was defined as every drug that
had been taken close enough prior to the onset of any symptom
(i.e., 21 days).
Final year medical students at The Aga Khan University
undertook the task of data collection. The biostatistical program,
Epi-Info (version 6.0) was used to analyze the gathered data.
Frequencies and percentages of relevant variables were obtained
and documented. The analysis is described below.

Results
Atotal of 101 patients were identified. The incidence of
SJS in the population was found to be 1.89 cases per million per
year. The mean age at presentation was 26.4 years with a standard
deviation of 19.8 years. There were 62 females and 39 males.
Amongst the female patients, 4 were pregnant at the time. Only
4 of the patients were from outside the city.
The predominant mode of presentation was primary
Stevens Johnson Syndrome while only 5 patients developed

patients could not provide information regarding the most likely
offender. Only one patient gave a history of meningitis
vaccination. No other vaccination history was given. The exact
dose of the administered drug was known in 48 cases, mode of
administration was oral in 95 patients and parenteral in 6. Twelve
patients gave a history of previous exposure to the offending
agent. Signs and symptoms (Figures 1and 2), complications
(Figure 3) and identity of offending drugs (Figure 4) are given in
their respective figures. Ninety patients were discharged from
the hospital after treatment while one patient was shifted to
another hospital. Ten patients died giving a mortality rate of
10.1%. Mortality was not affected by the type of drug
responsible.

Discussion
Stevens Johnson Syndrome (SJS) is an infrequently
encountered condition and we were able to review 101 individual
cases in a 10-year period at The Aga Khan University Hospital.
The study was consistent with other literature regarding age, that
it affected mainly the pediatric age group and young adults.
However, one particular study we came across did not achieve
this result.2
Our study revealed a male to female ratio of about 2:3.
Studies vary in this matter. Some quote male sex as a well-known
risk factor for the condition3 whereas some document that being
female carries a higher risk for these types of adverse drug
reactions.4-6

SJS secondary to treatment for another illness. Previous history
of SJS was positive in a total of 9 patients. The duration of
hospital stay was 10.2 days with a standard deviation of 8.9
days.
Of the 101 patients included in this study, 93 gave a
positive history of drug intake prior to developing the signs and
symptoms of Stevens Johnson Syndrome. Seven

Astudy of a primary presentation versus a secondary one
was undertaken to see if other illnesses predispose to SJS.
However, 96 of the patients presented with primary SJS and no
significant conclusion could be determined.
Amongst our 101 patients, 92 had no previous history of
SJS. A previous attack is a known risk factor for the development
of SJS.3 The general risk of recurrence of SJS is said to be about
37%, but our figures suggest a much lower percentage of about
8.9%.
Of the 101 cases reviewed, drugs were clearly one of
Of the 101 cases reviewed, drugs were clearly one of the
major offenders, contributing to about 93.9% of all cases, as
compared to 43% in a study in the United States7 and 54.5% in
Malaysia.8 This high incidence could be attributed to irrational,
unnecessary and easy 'over the counter' use of medicines in this
part of the world. Drugs are followed by infections (5.9%),
vaccines (0.1%) and the unknown category also being 0.1%.

Amongst drugs (Figure 4), antibiotics were the cause of
SJS in 67 cases (66.3%) making it the most common category of
drug. This tallies with some previously published studies.5,9-11
Amongst them the Penicillins had the highest incidence (30
cases) and the Sulphonamides had the second highest incidence
(26 cases) of causing SJS. The remaining drugs comprised of
Cepahalosporins, Macrolides, Tetracyclics and Quinolones.
When the drugs were analyzed on an individual basis (i.e.
taken out of their groups), Sulfadoxine-Pyrimethamine
(Fansidar) had the highest association with SJS; seen in 19 cases.
This is probably due to the high incidence of malaria endemic in
these parts of the world necessitating the use of cheaper antimalarials. This statement can be supported by the high incidence
of SJS in the inhabitants of Beira, Mozambique who were given
Fansidar for mass prophylaxis against cholera12 and in a study of
Swiss travelers using the same drug, they reported severe
cutaneous adverse reactions one thirtieth as large.13
NSAIDS accounted for 14 cases of SJS, which is
comparatively lower than other studies10,14,15, where NSAIDS
were responsible for about 50-74% of SJS cases. This could be
due to their relatively higher price in this country and cheaper
alternatives. Other drugs that caused single cases of SJS consisted
of Metronidazole, Diltiazem, Mebendazole and even one
reported case due to the ingestion of Smarties®. A study in
Thailand concluded that antituberculous drugs ranked third in
overall incidence when causing SJS but no case was reported
involving an antituberculous drug in our study even though
Pakistan is considered to be an endemic region for the disease.
This is in sharp contrast to a study in neighboring India. 16
A cause for the high incidence of drug related SJS could
be due to the fact that the indication of antibiotic use in some
cases may have been for the treatment of early signs and
symptoms of SJS due to other drugs. In one case, symptoms
deteriorated following Amoxicillin use and the general
practitioner involved increased the dose of the offending drug for
a further 7 days.
Concerning signs and symptoms (Figures 1 and 2), fever
was seen in 88 cases whereas ocular involvement occurred in 57
patients, making them the commonest nondermatological
manifestations of SJS in our study group.
This coincides with some studies done abroad.8 However,
patients with SJS in this study also presented with some
symptoms not found in standard literature or text. These included
dysuria (9 cases), edema (8 cases), dysphagia (6 cases) and
diarrhea (6 cases). The significance of these previously
undocumented outcomes following SJS requires further
investigations.
As regards to the complications during hospitalization
(Figure 3), the most commonly found ones were electrolyte
disturbances (14 cases) and congestive heart failure leading to
pulmonary edema (7 cases). Some complications, not previously
documented in standard medical literature, included
hematochezia (5 cases), hyperglycemia (3 cases) and depression
(1 case). Our complication rate was 59.4%. The study had a
relatively low occurrence of permanent visual changes in patients
following SJS. The rate of occurrence of permanent visual
change was 1.9%, whereas studies have reported the rate as high

as to 20%.2 Regular referrals and follow-ups by the
ophthalmologists were vital for this outcome.
The mortality in this group of patients was 10.1%, which
roughly coincides with studies done in the West where it is 4.515% of the patients. Acute hepatic failure was responsible for 2
deaths and sepsis was the cause of 1 mortality. No association
was found between the length of stay in the hospital and eventual
outcome. An interesting fact which came up in the analysis was
that one third of the patients that died had taken Amoxicillin as
the initial offender for SJS.

Conclusion
One hundred and one cases in ten years indicates that SJS
is a relatively rare condition. It is perhaps a first step for further
studies in the future, comparing results with other countries in the
region or even with that of toxic epidermal necrolysis (TEN), its
deadly counterpart. With a 10.1% mortality rate, which correlates
with the West, this syndrome should not be underestimated or
overlooked SJS is a hypersensitive reaction to a varied range of
etiologic factors and a large number of drugs may induce it. As
such, knowledge about this condition should modify a
physician's perception of the risk benefit balance of virtually any
drug. To investigate this further, a larger study would be needed.
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